In line with these experimental approaches, in silico drug repurposing strategies in Saudi research have pinpointed TP53, BRCA1/2, PIK3CA, and PARP1 as high‐priority targets for re‐sensitizing breast tumors to conventional therapies. Here, TP53 is linked to breast neoplasm.